Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplantWilliam Tse, Morris Kletzel, R. Duerst et al.|Bone Marrow Transplantation|2009Cited by 34
Single Daily Busulfan Dosing for Infants with Nonmalignant Diseases Undergoing Reduced-Intensity Conditioning for Allogeneic Hematopoietic Progenitor Cell TransplantationJessica Ward, William Tse, Morris Kletzel et al.|Transplantation and Cellular Therapy|2015Cited by 15
Allogeneic hematopoetic stem cell transplantation in pediatric myelodysplastic syndromes: Improved outcomes for <i>de novo</i> diseaseJeffrey R. Andolina, Sonali Chaudhury, Morris Kletzel et al.|Pediatric Transplantation|2011Cited by 14
Early mixed T‐cell chimerism is predictive of pediatric AML or MDS relapse after hematopoietic stem cell transplantLarisa Broglie, Sonali Chaudhury, Reggie Duerst et al.|Pediatric Blood & Cancer|2017Cited by 13
Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds ResultsMichael A. Pulsipher, Galen E. Switzer, Brent R. Logan et al.|Transplantation and Cellular Therapy|2018Cited by 11